Ivabradine Pill — Competitive Intelligence Brief

Ivabradine Pill (Ivabradine Pill) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: If channel inhibitor. Area: Cardiovascular.

marketed If channel inhibitor HCN (hyperpolarization-activated cyclic nucleotide-gated) channels Cardiovascular Small molecule

Target snapshot

Ivabradine Pill (Ivabradine Pill) — Tartu University Hospital. Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, reducing heart rate without affecting blood pressure or contractility.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ivabradine Pill TARGET	Ivabradine Pill	Tartu University Hospital	marketed	If channel inhibitor	HCN (hyperpolarization-activated cyclic nucleotide-gated) channels
Ivabradine + Usual Care	Ivabradine + Usual Care	The University of Hong Kong	marketed	If channel inhibitor	HCN (hyperpolarization-activated cyclic nucleotide-gated channel)
Ivabradine (Procoralan)	Ivabradine (Procoralan)	Medical University of Lodz	marketed	If channel inhibitor	HCN channel (hyperpolarization-activated cyclic nucleotide-gated channel)
Ivabradine and Metoprolol	Ivabradine and Metoprolol	Col. Suthee Panichkul	marketed	Combination: If channel inhibitor and beta-1 adrenergic antagonist	If channel (HCN4) and beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (If channel inhibitor class)

1. Medical University of Lodz · 1 drug in this class
2. Tartu University Hospital · 1 drug in this class
3. The University of Hong Kong · 1 drug in this class